Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
about
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Immune checkpoint therapy in liver cancer.The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challengesEngineering CAR-T Cells for Improved Function Against Solid Tumors
P2860
Q47221234-877BEC86-8C0C-494E-8C3B-B2D6F682368EQ47325431-7BD3F5F4-B861-4428-A721-DA7DF50DD164Q47862144-4AFBBB87-F468-4652-AF0A-A5E78D5BA644Q48337458-EFE42CBF-96C5-4253-B12C-63A8960F21DEQ52653710-8EFD7997-F2A8-4FF3-9492-9768764F414DQ55008806-121F460F-25A2-4BD3-97E4-4054CEFCB3CDQ55023271-664FDF84-F6AE-4989-B4D5-E1C80A3669DFQ55250324-C3C2EF82-D454-4415-88FD-E11B5491B690Q57162847-638444EF-04CC-4EA7-A9C3-BB67C2CF5D42Q58694793-A4D38261-3837-4140-8521-687E3EB872DC
P2860
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
@en
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
@nl
type
label
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
@en
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
@nl
prefLabel
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
@en
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
@nl
P2093
P2860
P1433
P1476
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
@en
P2093
Antonin Saldmann
Cecile Badoual
Charlotte Blanc
Eleonore De Guillebon
Elia Colin
Helene Roussel
Stephane Oudard
P2860
P304
P356
10.1136/ESMOOPEN-2017-000213
P577
2017-07-03T00:00:00Z